Companies›Consumer Discretionary›Realty›Realty
NSE:ALEMBICLTD

ALEMBIC LIMITED

Realty › Realty
₹87.65
at close · 28 Oct 2026
▼ 0.23 (-0.26%)

Latest filings

Next results: Fri, 6 Nov · Financial Results/Other business matters
  1. Board to approve September 2026 quarter and half-year results · Results
  2. Special window open for physical share dematerialisation · Compliance
  3. Quarterly dematerialisation compliance certificate filed for Q2 FY26 · Compliance
All filings ↓
Ask Nexa about ALEMBIC LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Operates two distinct businesses — real estate development and manufacture of active pharmaceutical ingredients (APIs). The Real Estate segment contributed 80.6% of FY26 segment revenue at ₹193.40 crore with an EBIT margin of 42.0%, while the API segment contributed 19.4% at ₹46.59 crore with a 12.1% EBIT margin. Standalone cost structure is dominated by other operating expenses at 39.9% of revenue and employee costs at 15.6%, while raw materials account for just 5.8% and depreciation 5.2%. Capex for the year was ₹38.25 crore (15.9% of revenue). Consolidated profits are heavily supplemented by the company's share of profits from associate Alembic Pharmaceuticals Limited, which contributed ₹19,145 lakh in FY26. Statutory auditors flagged a disputed electricity duty matter with a principal provision of ₹2,052.13 lakh and ₹3,500 lakh deposited with the Supreme Court. The Board has recommended a dividend of ₹2.40 per share (120% on face value) for FY26, unchanged from the prior year.

Revenue mix · reported segments
Real Estate Business80.6%
Active Pharmaceutical Ingredients Business19.4%
Operating scale
Real Estate segment revenue
₹193.40 croreFY26
Real Estate segment EBIT margin
42.0%FY26
API segment revenue
₹46.59 croreFY26
API segment EBIT margin
12.1%FY26
Share of associate profit (Alembic Pharmaceuticals)
₹19,145 lakhFY26
Dividend declared
₹2.40 per share (120%)FY26
Who pays it
Real estate buyers for the property segment; pharmaceutical companies for the API segment.
Biggest cost
Other operating expenses, the largest line at 39.9% of FY26 revenue.
Kind of business
Diversified group with a real-estate-led top line, a smaller API manufacturing business, and consolidated earnings heavily lifted by an associate stake in Alembic Pharmaceuticals.
Where it sits
Real Estate accounts for roughly four-fifths of segment revenue, while consolidated profit is materially dependent on associate company Alembic Pharmaceuticals Limited.
Market Cap
₹2,251 Cr
P / E (TTM)
7.0×
EV / EBITDA
14.0×
Div Yield
2.73%
Growth
26.7%▲
Revenue 5y CAGR
PAT -1.5% · EBITDA +50.2%
Quality
4.6%·
ROCE (5y median)
ROE 12.3% (5y median) · margin 68.1%
Leverage
0.00·
Debt / Equity · low
Net debt ₹9.23 Cr
Revenue FY21→FY26
3.3×▲
Margin −334.1 pts
₹74 Cr → ₹240 Cr
Cash conversion
0.19×▼
Operating cash ÷ profit · 5 yrs
₹250 Cr on ₹1,309 Cr
Moves on a normal day
1.23%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 66 Residential Commercial Projects peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#4/57
P/B#17/64
ROCE#34/66
ROE#15/64
Debt / Equity#8/64
EBITDA margin#13/66
Revenue growth#48/67
Profit growth#35/66

Scorecard

Measured from the filed financials, judged against its Residential Commercial Projects peers · as of FY26 — not investment advice

Strengths
Revenue compounding 27% a year over 5 years
Debt at 0.00× equity
lower than 89% of its 64 Residential Commercial Projects peers
Concerns
Profit shrinking over 5 years (−2% a year)
Returns on capital 4.6% (5-year median)
#34 of 66 in Residential Commercial Projects on the latest reported figures · up from 0.7% in FY21
Over 5 years it reported ₹1,309 Cr of profit and ₹250 Cr of operating cash — 0.19×
Less than 60p of every ₹1 of profit arrived as cash

Charts

How has the market priced it — with filings on the timeline?

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from ALEMBIC LIMITED's filed financials and exchange disclosures

What does ALEMBIC LIMITED do?

ALEMBIC LIMITED is a Realty company listed on NSE and BSE, trading under the symbol ALEMBICLTD.

Is ALEMBIC LIMITED profitable?

Yes. Over the trailing twelve months ALEMBIC LIMITED reported a net profit of ₹321 Cr on revenue of ₹239 Cr.

Does ALEMBIC LIMITED pay a dividend?

Yes. The dividend yield is 2.73% at the current price. It paid out 19% of its profit as dividend in FY26.

Is ALEMBIC LIMITED debt-free?

No. It reported borrowings of ₹11 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹9.23 Cr after cash. Debt stands at 0.00× equity. That is lower than 89% of its 64 Residential Commercial Projects peers.

Is ALEMBIC LIMITED expensive compared with its peers?

On trailing P/E, ALEMBIC LIMITED ranks 4 of 57 in Residential Commercial Projects — cheaper than 95% of them, against an industry median of 20.5×. This is a position, not a valuation judgement.

How much does the ALEMBIC LIMITED share price move in a day?

On a typical session ALEMBIC LIMITED moves 1.23% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are ALEMBIC LIMITED's next results?

Financial Results/Other business matters on Fri, 6 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track ALEMBIC LIMITED's announcements?

Every NSE and BSE filing by ALEMBIC LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.